Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
GemPharmatech CoSHSE:688046 +4.25%77 Days Payable is 76.20 as of Jun. 2026, which is 46% below its 10-year median of 140.71. GuruFocus rates SHSE:688046 with a GF Score™ of 77/100 and a GF Value™ of ¥19.65 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 706 Biotechnology companies, GemPharmatech Co ranks worse than 57.22% on this metric.
The historical rank and industry rank for GemPharmatech Co's Days Payable or its related term are showing as below:
SHSE:688046'
s Days Payable Range Over the Past 10 Years
Min: 81.19 Med: 140.71 Max: 575.14
Current: 81.19
During the past 8 years, GemPharmatech Co's highest Days Payable was 575.14. The lowest was 81.19. And the median was 140.71.
SHSE:688046's Days Payable is ranked worse than 57.22% of 706
companies
in the Biotechnology industry
Industry Median: 111.165
vs SHSE:688046: 81.19
GemPharmatech Co's Days Payable
declined
from Jun. 2025 (82.48) to Jun. 2026 (76.20).
It may suggest that GemPharmatech Coaccelerated paying its suppliers.
The historical data trend for GemPharmatech Co's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:688046 vs VRTX, REGN, MRNA: Days Payable Comparison
For the Biotechnology subindustry, GemPharmatech Co's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GemPharmatech Co Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, GemPharmatech Co's Days Payable distribution charts can be found below:
* The bar in red indicates where GemPharmatech Co's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
GemPharmatech Co's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GemPharmatech Co (SHSE:688046) has a Days Payable of 76.20 as of Jun. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on GemPharmatech Co and its competitors. This is 46% below median its historical median of 140.71. Over the past decade, GemPharmatech Co's Days Payable has ranged from 81.19 to 575.14. According to the industry distribution chart, GemPharmatech Co ranks #404 out of 706 companies in the Biotechnology industry, placing it in the top 57.2%.
Is GemPharmatech Co's Days Payable too high?
GemPharmatech Co's current Days Payable of 76.20 is 46% below median its 10-year median of 140.71. Over the past 10 years, this metric has ranged from a low of 81.19 to a high of 575.14. The Biotechnology industry median Days Payable is 111.17. GemPharmatech Co's value of 76.20 is 31.5% below this industry median. Based on the distribution chart, GemPharmatech Co ranks #404 out of 706 companies in the Biotechnology industry, which is below the industry midpoint. Overall, GemPharmatech Co has a GF Score™ of 77/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does GemPharmatech Co's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, GemPharmatech Co ranks #404 out of 706 companies for Days Payable. This places GemPharmatech Co in the lower half of its industry. The industry median Days Payable is 111.17. GemPharmatech Co's value of 76.20 is 31.5% below this benchmark. Historically, GemPharmatech Co's own Days Payable has ranged from 81.19 to 575.14 over the past decade. While the company's 10-year median is 140.71 vs. the industry median of 111.17, GemPharmatech Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 111.17, based on 706 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. GemPharmatech Co's current Days Payable of 76.20 is 31.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on GemPharmatech Co and its competitors. For the Biotechnology industry, the median Days Payable is 111.17 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. GemPharmatech Co's current Days Payable is 76.20, which is 46% below median its own 10-year median of 140.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GemPharmatech Co stock overvalued right now?
Based on GuruFocus' analysis, GemPharmatech Co (SHSE:688046) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥19.65, compared to a current price of ¥36.78 — trading 87.2% above its estimated fair value. The current Days Payable is 76.20, which is 46% below median its 10-year median of 140.71 and 31.5% below the Biotechnology industry median of 111.17. GemPharmatech Co's overall GF Score™ is 77/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For GemPharmatech Co (SHSE:688046), the current Days Payable is 76.20 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is GemPharmatech Co (SHSE:688046) Overvalued in 2026?
Based on GuruFocus' analysis, GemPharmatech Co stock appears to be overvalued.
The current stock price of ¥36.78 is trading 87.2% above its estimated GF Value™ of ¥19.65.
GuruFocus considers GemPharmatech Co to be Significantly Overvalued.
Key valuation signals for SHSE:688046:
Days Payable: 76.20 (46% below median its 10-year median of 140.71)
GF Value™: ¥19.65 vs. price of ¥36.78 (87.2% above fair value)
Industry Position: 31.5% below the Biotechnology median (#404 of 706)
No single metric tells the full story. See the SHSE:688046 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
GemPharmatech Co Ltd is a provider of genetically engineered mouse models and services to preclinical research and development communities. The company develops mouse models with independent intellectual property rights based on technical platforms such as gene editing, stem cells, phenotypic analysis, efficacy analysis, and sterile animals, and carries out one-stop services such as model customization, customized breeding, and functional efficacy analysis.
77GF Score
Get the complete analysis for SHSE:688046
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688046 has been successfully added to your 
